Skip to main content
$73.30 $3.80 (5.5%)

04:00 PM EDT on 07/01/22

NovoCure (NASDAQ:NVCR)

CAPS Rating: 5 out of 5

Current Price $73.30 Mkt Cap $7.7B
Open $69.35 P/E Ratio 0.00
Prev. Close $73.30 Div. (Yield) $0.00 (0.0%)
Daily Range $69.05 - $73.31 Volume 428,193
52-Wk Range $56.39 - $195.78 Avg. Daily Vol. 781,759

Caps

How do you think NASDAQ:NVCR will perform against the market?

Add Stock to CAPS Watchlist

All Players

436 Outperform
1 Underperform
 

All-Star Players

48 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:NVCR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Reserved1 (< 20)
Submitted January 07, 2022

Medical research with little to no competition

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:NVCR Summary

Fools bullish on NASDAQ:NVCR are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about NVCR.

Recs

0
Member Avatar Foolme21 (< 20) Submitted: 3/10/2022 12:20:15 PM : Outperform Start Price: $64.66 NASDAQ:NVCR Score: +21.58

TTFields have extended overall patient survival for glioblastoma (GBM). Based on successful GBM treatment and research indicating that TTFields can improve treatment for other cancers, Novocure's TAM will greatly expand. Results from the LUNAR (non-small cell lung cancer, NSCLC) and INNOVATE-3 (ovarian cancer) phase 3 clinical trials are due later in 2022/2023, respectively. If trials indicate TTFields extend patient survival beyond GBM, then NovoCure will outperform the S&P 500.

Recs

1
Member Avatar Reserved1 (< 20) Submitted: 1/7/2022 10:18:28 AM : Outperform Start Price: $68.92 NASDAQ:NVCR Score: +23.89

Medical research with little to no competition

Recs

1
Member Avatar willieram (< 20) Submitted: 11/22/2021 1:07:53 PM : Outperform Start Price: $97.69 NASDAQ:NVCR Score: -6.60

Fourth method for cancer treatment. Non invasive technology, no side effects, potentially able to treat most tumors. Revolutionary.

Leaderboard

Find the members with the highest scoring picks in NVCR.

Score Leader

oldlumike

oldlumike (37.81) Score: +529.29

The Score Leader is the player with the highest score across all their picks in NVCR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. stcksrus 74.54 7/27/2016 7/29/2021 Outperform 5Y $11.69 +521.98% +75.57% +446.41 0 Comment
synapse 66.49 10/20/2017 Outperform 5Y $18.25 +298.41% +48.55% +249.86 0 Comment
findil 53.05 10/23/2017 Outperform 5Y $18.43 +294.63% +48.29% +246.34 1 Comment
SuzyP99 74.05 8/23/2017 Outperform 1Y $18.75 +287.79% +56.07% +231.72 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. skyrocket29 65.27 8/22/2017 Outperform 1Y $19.10 +280.68% +56.55% +224.13 0 Comment
tprooney3 94.51 7/17/2017 Outperform 5Y $19.25 +277.71% +55.34% +222.37 1 Comment
XMFpessen 43.23 12/5/2017 Outperform 5Y $19.95 +264.55% +44.30% +220.26 0 Comment
only1ferret 50.10 12/6/2017 Outperform 5Y $20.08 +262.19% +44.67% +217.52 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. ATrain 36.35 12/21/2017 Outperform 5Y $20.25 +259.06% +42.42% +216.64 0 Comment
TMFTypeoh 91.88 4/3/2018 Outperform 5Y $20.05 +262.64% +47.43% +215.21 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NVCR.